This is a news story, published by CNBC, that relates primarily to RSV news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
outside vaccine advisors. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other immunizations news, RSV shots news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
VaccinesCNBC
•Health
Health
87% Informative
Merck 's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus .
The approval gives doctors a new treatment option for the virus, which causes thousands of deaths among older Americans .
Complications from RSV are the leading cause of hospitalization among newborns.
The FDA paused testing of RSV shots in young children while it evaluates safety concerns.
VR Score
90
Informative language
92
Neutral language
50
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
3
Source diversity
3
Affiliate links
no affiliate links
